Table 1.
Antineoplastic agents that induce Takotsubo syndrome
| Antineoplastic agents | Indicative references |
|---|---|
| Antimetabolites | |
| 5‐Fluorouracil |
Lim SH, et al. Case Rep Oncol Med. 2013;2013:206765. Valero M, et al. J Geriatr Oncol. 2020 Nov;11(8):1337–1339. Kobayashi N, et al. J Nippon Med Sch. 2009 Feb;76(1):27–33. Ozturk MA, et al. Blood Coagul Fibrinolysis. 2013 Jan;24(1):90–4. Kumar D, et al. Cureus. 2021 Mar 22;13(3):e14049. Basselin C, et al. Pharmacotherapy. 2011 Feb;31(2):226. Knott K, et al. Int J Cardiol. 2014 Dec 15;177(2):e65–7. De Pasquale MD, et al. BMC Pediatr. 2016 Jul 19;16:99. Stewart T, et al. Intern Med J. 2010 Apr;40(4):303–7. Gianni M, et al. Blood Coagul Fibrinolysis. 2009 Jun;20(4):306–8. Coen M, et al. BMC Cancer. 2017 Jun 2;17(1):394. Kobayashi N, et al. J Nippon Med Sch. 2009;76(1):27–33. Cheriparambil KM, et al. Angiology. 2000;51(10):873–8. Dalzell JR, et al. Anti‐Cancer Drugs. 2009;20(1):79–80. Grunwald MR, et al. J Clin Oncol. 2012, 10;30(2):e11–4. |
| Capecitabine |
Bhardwaj PV, et al. Perm J. 2019;23:18–245. Qasem A, et al. Am J Ther. 2016 Sep–Oct;23(5):e1188–92 Abdelmaseih R, et al. Curr Probl Cardiol. 2021 Aug;46(8):100854. Powers A et al. J Am Coll Cardiol 2020;75(11 Supplement 1):3279. Sabharwal S, et al. Chest 2018;54(4 suppl):107A. Sakamoto T, et al. J Cardiac Fail 2016;Vol. 22. No. 9S September. Stewart T, et al. Intern Med J 2010;40(4):303–7. Y‐Hassan S, et al. Cardiovasc Revasc Med 2013;14(1):57–61. Ang C, et al. Curr Oncol 2010;17(1):59–63. Klag T, et al. Clin Res Cardiol. 2014 Mar;103(3):247–50. Endo A, et al. Int Heart J. 2013;54(6):417–20. Molteni LP, et al. Breast J. 2010;16(s1):S45–8. |
| Cytarabine |
Baumann S, et al. Oncol res Treat. 2014;37(9):487–90. Madias JE. Oncol Res Treat. 2015;38(3):125. |
| Anthracyclines/topoisomerase II inhibitors | |
| Doxorubicin | Mubarak G, et al. Clin Case Rep. 2019 Nov 8;7(12):2466–71. |
| Plant alkaloids/topoisomerase I inhibitors | |
| Irinotecan | Kim L, et al. J Invasive Cardiol. 2008 Dec;20(12):E338–40. |
| HER2 inhibitors | |
| Trastuzumab |
Burgy M, et al. Anticancer Res. 2014;34(7):3579–82. Khanji M, et al. Clin Oncol (R Coll Radiol). 2013;25(5):329. Matsumoto T, et al. Int Cancer Conf J. 2019 Dec 6;9(1):28–31. Lees C, et al. Oncologist. 2019 Feb;24(2):e80–2. |
| Platinum compounds | |
| Cisplatin | Hannan A, et al. Pak J Med Sci. 2018 Jul–Aug;34(4):1030–3. |
| Other monoclonal antibodies | |
| Rituximab |
Smith SA, et al. Heart Fail Clin. 2013;9(2):233–42. X Ng KH, et al. BMJ Case Rep. 2015;2:2015. |
| Cetuximab | Kim L, et al. J Invasive Cardiol. 2008 Dec;20(12):E338–40. |
| Anti‐VEGF antibodies | |
| Bevacizumab | Franco TH, et al. Ther Clin Risk Manag. 2008;4(6):1367–70. |
| Immune checkpoint inhibitors (ICIs) | |
| Ipilimumab | Geisler BP, et al. J Immunother Cancer. 2015;3:4. |
| Pembrolizumab | Ederhy S et al. Eur J Heart Fail. 2019 Jul;21(7):945–7. |
| Nivolumab | Ederhy S et al. Eur J Heart Fail. 2019 Jul;21(7):945–7. |
| Ipilimumab + nivolumab | Oldfield, et al. BMJ Case Reports vol. 14,2 e237217. 1 Feb. 2021. |
| Multitargeted tyrosine kinase inhibitors (TKIs) | |
| Ibrutinib | Giza DE, et al. Eur Heart J Case Rep. 2017 Nov 2;1(2):ytx006. |
| VEGF signalling pathway inhibitors | |
| Axitinib | Ovadia D, et al. J Clin Oncol. 2015, 1; 33(1):e1–3. |
| Sunitinib | Numico G, et al. J Clin Oncol. 2012, 20;30(24):e218–20 |
| Regorafenib | Arunachalam K, et al. R I Med J (2013). 2020 Dec 1;103(10):40–3. |
| Miscellaneous agents | |
| Combretastatin | Bhakta S, et al. Clin Cardiol. 2009;32(12):E80–4. |
| Combination therapy | |
| Cisplatin + docetaxel | Toyooka S, et al. Gen Thorac Cardiovasc Surg. 2012 Sep;60(9):599–602. |
| Cytarabine + daunorubicin | Goel S, et al. World J Clin Cases. 2014 Oct 6;2(10):565–8. |
| Vinorelbine + capecitabine | |
| FOLFOX (folinic acid, fluorouracil, and oxaliplatin) |
Ali S, et al. Journal of Hospital and Medical Management 2021. Sundaravel S, et al. Case Rep Cardiol. 2017;2017:8507096. Basselin C, et al. Pharmacotherapy. 2011;31(2):226. Yeh ET, et al. Circulation. 2004;109(25):3122–31. Stewart T, et al. Intern Med J. 2010;40(4):303–7. Parker WB, et al. Pharmacol Ther. 1990;48(3):381–95. Ozturk MA, et al. Blood Coagul Fibrinolysis. 2013;24(1):90–4. |
| mFOLFOX6 | Saif MW et al. Cureus. 2016 Sep 14;8(9):e783. |
| Gemcitabine + vinorelbine | Özbay B, et al. Turk Kardiyol Dern Ars. 2021 Jan;49(1):72–5 |
| Carboplatin + pemetrexed + pembrolizumab | Khan NAJ, et al. Cureus. 2020 Jul 27;12(7):e9429. |
| Paclitaxel + hydroxyurea + 5‐FU and radiotherapy | Schweizer MT, et al. J Clin Oncol. 2011, 10;29(20):e598–e600. |
| Cisplatin + 5‐FU + methotrexate + mitomycin + bleomycin | Coen M, et al. BMC Cancer. 2017 Jun 2;17(1):394. |
| Combretastatin + cisplatin + doxorubicin |
Cheungpasitporn W, et al. J Renal Inj Prev. 2017;6(1):18–25. |
| Rituximab + methylprednisolone | Ovadia D, et al. J Clin Oncol. 2014;33(1):e1–3. |
| Trastuzumab + docetaxel + carboplatin | Norwood TG, et al. J Immunother Cancer. 2017;5(1):91. |
| Cisplatin + 5‐FU |
Dalzell JR, et al. Anti‐Cancer Drugs. 2009;20(1):79–80. Tsibiribi P, et al. Bull Cancer. 2006;93(3):10027–30. |
| DCF + FOLFIRI | Becker K, et al. Drugs. 1999;57(4):475–84. |
| 5‐FU + levofolinate | Naranjo CA, et al. Clin Pharmacol Ther. 1981;30(2):239–45. |
| Daunorubicin + cytarabine + doxorubicin | Voit, J., et al. BMJ Case Reports, 2018, bcr2018226378. |
| Pembrolizumab + trastuzumab | Anderson RD, et al. Int J Cardiol. 2016 Nov 1;222:760–1 |
| Ipilimumab + nivolumab | Ederhy S, et al. JACC Cardiovasc Imaging. 2018 Aug;11(8):1187–90. |
| Trastuzumab + pertuzumab + nab‐paclitaxel | Lees C, et al. Oncologist. 2019 Feb;24(2):e80–2. |